The reason I had to use 3-year mark is because that was the only one available for Rigicon Infla10. Sort of to compare apples to apples. FT doesn't allow to paste tables so had to rearrange table manually
At the 3-year mark, the Rigicon Infla10 demonstrates equivalent revision-free and mechanical survival rates (93.7%–97.6%) to modern iterations of both the Coloplast Titan and Boston Scientific AMS 700 (CX and LGX). [1, 2, 3]
Clinical studies show that across all three brands, the vast majority of devices remain intact and complication-free during the first 36 months. [1, 2, 3]
3-Year Survival Rate Comparison:
Rigicon Infla10 (AX & X)
3-Year Overall Revision-Free Survival: 93.7% – 97.6% (95.65%)
3-Year Mechanical Survival (Breakage-Free): ~97.0% – 97.8% (97.4%).
Key Clinical Context: Derived from post-2019 multicenter studies (e.g., 535-patient Urology cohort).
Coloplast Titan
3-Year Overall Revision-Free Survival: ~91.0% – 95.0% (93%)
3-Year Mechanical Survival (Breakage-Free): ~96.0% – 98.0% (97%)
Key Clinical Context: Reflects modern Titan models with reinforced zero-angle tubing and hydrophilic coatings.
AMS 700 (CX & LGX)
3-Year Overall Revision-Free Survival: ~91.0% – 96.0% (93.5%)
3-Year Mechanical Survival (Breakage-Free): ~97.9%
Key Clinical Context: Reflects contemporary models with Parylene-coated cylinders and InhibiZone antibiotic treatment.
Important Distinctions in the 3-Year Data
• Overall Survival vs. Mechanical Survival. Studies report two different metrics. Overall revision-free survival (91%–97.6%) includes reoperations for any reason, such as infection, pump malposition, or patient dissatisfaction. Mechanical survival (96%–98%) strictly tracks device breakage or fluid leaks, where all three modern brands perform nearly identically. [1, 2, 3, 4, 5]
• Pooled Meta-Analysis Benchmarks. A major 2022 systematic review in Urology analyzing over 20,000 patients found an industry-wide 3-year overall device survival rate of 91.0%. Because that figure includes older device generations from the 1990s and 2000s, contemporary cohorts of Titan, AMS 700, and Infla10 all beat that historical baseline.[1, 2, 3, 4]
• CX vs. LGX and X vs. AX at 3 Years. Within the first 36 months, clinical data shows no meaningful survival gap between girth-only cylinders (AMS 700 CX, Infla10 X) and length-and-girth cylinders (AMS 700 LGX, Infla10 AX). Differences in cylinder wear—such as potential aneurysm or fatigue in length-expanding cylinders—typically emerge after the 5-to-7-year mark rather than in the first 3 years.
• Surgeon Volume Factor. Across 3-year datasets for all three manufacturers, early revision rates are driven more by surgical factors (infection control, reservoir placement, and sizing accuracy) than by material differences between Bioflex (Titan) and multi-layered silicone (AMS 700 and Infla10). [1, 2, 3]
All 3 brands look comparable no matter what your doctor tells you. Pick you poison.
